Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.37 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.36 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
| ▸ | TK2 | O00142 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | POLD1 | P28340 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442262 | 1.00 | TK1 (0.37) | TK1NT5MRNASE1TK2POLB | |
| SCHEMBL24368542 | 1.00 | TK1 (0.37) | TK1NT5MRNASE1TK2POLB | |
| SCHEMBL16158928 | 0.97 | TK1 (0.38) | TK1NT5MRNASE1TK2POLB | |
| SCHEMBL16158915 | 0.94 | TK1 (0.39) | TK1NT5MRNASE1POLBPOLA1 | |
| SCHEMBL14980357 | 0.91 | TK1 (0.36) | TK1NT5MRNASE1TK2POLB | |
| SCHEMBL14980435 | 0.91 | TK1 (0.36) | TK1NT5MRNASE1TK2POLB | |
| SCHEMBL16158935 | 0.90 | TK1 (0.38) | TK1NT5MRNASE1TK2POLB | |
| SCHEMBL18739038 | 0.90 | TK1 (0.41) | TK1NT5MRNASE1TK2POLB | |
| SCHEMBL16219524 | 0.90 | TK1 (0.38) | TK1NT5MRNASE1TK2POLB | |
| SCHEMBL16158930 | 0.89 | NT5M (0.37) | TK1NT5MRNASE1TK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-13 | — | — | US | disclosed |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-09-03 | — | — | US | disclosed |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170198287-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-07-13 | — | — | US | disclosed |
| US-9469664-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9161948-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | TK1 559/4885NT5M 3336/4885RNASE1 79/4885 |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | TK1 559/4885NT5M 3336/4885RNASE1 79/4885 |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | TK1 217/4885NT5M 3775/4885RNASE1 9/4885 |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | TK1 418/4885NT5M 3073/4885RNASE1 56/4885 |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | TK1 418/4885NT5M 3073/4885RNASE1 56/4885 |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | NSUN2, UPF1, RTCB | TK1 559/4885NT5M 3336/4885RNASE1 79/4885 |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | TK1 217/4885NT5M 3775/4885RNASE1 9/4885 |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | TK1 559/4885NT5M 3336/4885RNASE1 79/4885 |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | TK1 418/4885NT5M 3073/4885RNASE1 56/4885 |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | TK1 418/4885NT5M 3073/4885RNASE1 56/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | TK1 217/4885NT5M 3775/4885RNASE1 9/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | TK1 418/4885NT5M 3073/4885RNASE1 56/4885 |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | TK1 217/4885NT5M 3775/4885RNASE1 9/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | TK1 217/4885NT5M 3775/4885RNASE1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.